Groupe d'Etude en Oncologie du Quebec

Titre	Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma: a Pilot Study.
Protocole ID	2022-6186
ClinicalTrials.gov ID	NCT05340569
Type(s) de cancer	Pancréas
Phase	Autres
Type étude	Diagnostic
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL HOPITAL DE L'ENFANT-JESUS 1401 18e Rue, Québec, QC, G1J 1Z4
Ville	Québec
Investigateur(trice) principal(e)	Dr Alexandre Brind’Amour
Coordonnateur(trice)
Statut	Actif en recrutement
Date d'activation	06-04-2022
Critètes d'éligibilité	Confirmed diagnosis of pancreatic ductal adenocarcinoma. Resectable disease or borderline resectable disease based on CT. Tumor size ≥ 3 cm. CA 19-9 ≥ 400 U/mL with normal bilirubin level (< 40) No evidence of distant metastases. Patient fit for pancreatic resection (ECOG 0 or 1).
Critètes d'exclusion	Impossibility to obtain tissue diagnosis preoperatively confirming pancreatic ductal adenocarcinoma. Locally advanced disease on CT. Tumor size < 3 cm. CA 19-9 < 400 U/mL or CA 19-9 ≥ 400 U/mL with no preoperative drainage. Suspicion of distant metastases, including peritoneal metastases, on CT. Patient who is unable to have MRI. Patient unfit for pancreatic resection (ECOG 2 or more).

Groupe d'étude en oncologie du Québec